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RETROSPECTIVE AND REAL-TIME SEMICONDUCTOR 
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equal	 to	 the	 rate	 of	 energy	 emission	 per	 unit	 mass	 (Aitken,	 1985).	 Dose	 rate	


































































































































































































































































































































































radioactive	 hot-spots	 distributed	 inside	 (figure	 4.6a).	 Biotite	 spheres	 were	
embedded	in	a	block	of	resin	and	measured	on	the	Timepix	for	6	days.	The	2D	pixel-
by-pixel	 hitmap	 is	 shown	 in	 figure	 4.6b,	 with	 the	 eight	 biotite	 spheres	 clearly	













again	 held	 together	 by	 resin.	Monazite	was	 selected	 as	 an	 additional	 high-activity	
natural	mineral	containing	high	concentrations	of	thorium.	The	results	of	the	5-day	
measurement	are	shown	on	the	2D	hitmap	in	figure	4.7.	Monazite	proved	to	be	even	








resolved	 Timepix	 count	 distribution.	 The	 next	 step	 was	 to	 assess	 the	 detector’s	





































































Preliminary	 feasibility	 studies	 employing	 real	 and	 artificial	 samples	 of	 high	 and	




























This	 involved	 both	 MC	 simulations	 and	 experimental	 methods.	 Both	 relative	 and	






MC	 simulations	 were	 used	 to	 facilitate	 Timepix	 method	 development,	 addressing	






an	 overlaid	 grid	 containing	 a	 256	 x	 256	 voxelized	 readout	 geometry,	 emulating	







The	 first	 simulation	 serving	 as	 validation	 for	 the	 geometry	 and	 40K	 decay	 was	 a	
reproduction	of	 the	biotite	study	described	 in	section	4.2.3.1.	The	results	of	 the	1-
week	measurement	simulation	are	shown	in	figure	5.1,	with	the	number	of	particles	
per	unit	energy	(keV)	plotted	as	a	function	of	the	energy	deposition	in	the	Timepix.	






























































































































































































Mueller	 (GM)	 tubes	 and	 a	 common	 guard	 counter	 [68,	 69].	 The	 beta	 counter	 is	
housed	inside	a	10	cm-thick	Pb	bunker	to	reduce	background	interactions.	A	sample	











measurement	 was	 run	 for	 24	 hours	 using	 1-hour	 cycles	 that	 simultaneously	
measure	the	5	samples.	
	
To	 convert	 the	 measured	 count	 rate	 into	 dose	 rate,	 the	 three	 replicate	 sample	
measurements	were	averaged	and	compared	against	Nussi,	following	subtraction	of	
the	 background	 count	 rate.	 The	 dose	 rate	 was	 then	 determined	 using	 previously	
established	conversion	 factors	 [38].	The	errors	associated	with	 the	 final	dose	 rate	







The	 post-cluster	 analysis	 beta	 particle	 count	 rates	 calculated	 for	 the	 uniform	
(central)	 region	 of	 the	 sample	 on	 the	 Timepix	 detector	 for	 the	 five	 calibration	
samples	are	plotted	against	the	corresponding	dose	rates	measured	using	the	beta	
counter	 in	 figure	 5.7.	 A	 calibration	 curve	 was	 derived	 to	 convert	 the	 Timepix-
measured	count	rate	into	beta	dose	rate:	
















































































Dr	(K)	=	2.9E+06	*	CTpx	 	 	 	 (5.3)	
Dr	(Th)	=	3.6E+06x	*	CTpx	 	 	 	 (5.4)	
































































































A	 micro-stratified	 sample	 was	 prepared	 as	 per	 Timepix	 sample	 preparation	
procedure	(section	5.3.1),	using	200–350	μm-diameter	grains	of	quartz	and	biotite.	












pixels)	 are	 shown	 on	 a	 2D	 hit	 map	 in	 figure	 6.1a,	 with	 the	 scale	 on	 the	 right	
corresponding	 to	 the	 number	 of	 counts	 per	 pixel	 cluster	 (c/p).	 The	 two	 sample	
components	 are	 clearly	 visible	 based	 on	 their	 count	 rates,	 plotted	 as	 the	 x-y	









a	 resolution	 of	 0.88	 x	 0.88	 mm2	(16x16	 pixels).	 40K	 dose	 rates	 were	 determined	
using	 the	absolute	potassium	calibration	curve,	and	range	between	 -0.16	and	3.57	
Gy/ka.	The	dose	rates	attributed	to	the	biotite	regions	of	the	sample	range	between	



















rate	 values	 resulted	 following	 background	 adjustment.	 Dose	 rates	 below	 0	 were	
found	in	regions	of	low	count	rates	and	are,	therefore,	considered	to	be	statistically	
insignificant.	 This	 is	 further	 demonstrated	 by	 the	 error	 bars	 on	 the	 x-profile	 in	


















Liang	 Bua	 and	 Denisova	 Cave	 are	 both	 sites	 where	 archaic	 hominins	 have	 been	
discovered	 in	 recent	 decades:	 the	Homo	 floresiensis	 at	 Liang	 Bua,	 located	 on	 the	
eastern	 Indonesian	 island	 of	 Flores	 [72-74],	 and	 Denisovans	 and	 Neanderthals	 at	
Denisova	Cave,	located	in	the	Altai	Mountains	of	southern	Siberia,	Russia	[4,	75,	76].	
Robust	 dating	 methods	 are	 necessary	 to	 establish	 a	 reliable	 timeline	 for	 these	














































shown	 in	 figures	 6.4	 and	 6.5,	 respectively.	 In	 each	 of	 these	 figures,	 the	 first	 two	
columns	on	the	left	correspond	to	the	front	side	of	the	sample,	and	the	second	two	
columns	 correspond	 to	 the	 back	 of	 the	 sample.	 In	 the	 Liang	 Bua	 profile,	 the	 beta	
dose	rates	 range	between	0	and	4	Gy/ka,	with	a	mean	value	of	0.71	Gy/ka.	 In	 the	
Denisova	Cave	sample	profile,	the	dose	rate	ranges	between	0	and	5.4	Gy/ka,	with	a	












Cave	 profile	 has	 a	 mean	 dose	 rate	 2.3	 times	 higher	 than	 that	 of	 the	 Liang	 Bua	
sample.	 This	 difference	 can	 also	be	 seen	on	 the	2D	dose	 rate	hit	maps	of	 the	 two	
samples,	 where	 the	 Liang	 Bua	 samples	 contain	 radiation	 hotspots	 surrounded	 by	
non-active	 regions,	 whereas	 the	 Denisova	 Cave	 sediments	 have	 a	 more	 uniform	
radioactivity	 distribution.	 The	 results	 of	 both	 profile	 sample	 measurements	
demonstrate	 the	 variable	 extent	 of	 sample	 beta	 inhomogeneity	 and	 its	 relation	 to	
the	 specific	 architecture	 of	 the	 sample	 under	 investigation	 (e.g.,	 presence	 of	




















not	 visible	 on	 the	 plot.	 While	 the	 Denisova	 Cave	 sample	 dose	 rate	 distribution	
appears	moderately	Gaussian	 in	 shape,	distributed	around	a	value	of	2	Gy/ka,	 the	










The	 errors	 in	 the	 derived	 dose	 rates	 depend	 on	 the	 spatial	 resolution	 (i.e.,	 the	
binning	of	the	resulting	single	pixel	data).	Spatial	resolution	of	0.44	x	0.44	mm2	(8x8	
pixels,	figures	6.4	and	6.5)	results	in	a	relative	error	of	27.7%	for	the	mean	dose	rate	
of	 0.71	 Gy/ka	 in	 the	 Liang	 Bua	 sample,	 for	 a	measurement	 time	 of	 10	 days.	 The	
relative	error	decreases	 to	14.1%	and	7.5%	 for	 spatial	 resolutions	of	0.77	 (16x16	
pixels)	and	3.10	mm2	(32x32	pixels),	 respectively.	Radiation	hotspots	 in	 the	Liang	
Bua	 sample,	 shown	 in	 red	 on	 the	 dose	 rate	 heat	 maps	 in	 figure	 6.4	 and	
corresponding	to	dose	rates	of	2	Gy/ka	and	higher,	have	maximum	relative	errors	of	
16.7%	and	5.0%	for	resolutions	of	0.19	and	3.10	mm2,	respectively.	In	the	Denisova	
Cave	 profile,	 the	 relative	 errors	 for	 the	mean	dose	 rate	 of	 1.65	Gy/ka	 range	 from	
18.3%	 to	 5.3%	 for	 spatial	 resolutions	 of	 0.19	 to	 3.10	 mm2,	 respectively.	 The	
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ΔVTH	~	0.0022	!	D0.4		!	t2ox		 (passive	mode)	 	 	 (8.1)	
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































distal	 tip	 of	 the	 applicator	 (with	 respect	 to	 the	 afterloader)	 was	 chosen	 as	 the	
reference	 point	 for	 determining	 the	 source	 location	 within	 the	 applicator.	 The	 first	







were	 evaluated	using	 a	Matlab	 script	 to	 determine	 the	 center	 of	 each	 192Ir	 exposure	
and	its	location	with	respect	to	the	edge	of	the	film	(figure	9.16).	The	distances	(mm)	
from	the	applicator	surface,	±	0.1mm	(k=1),	were	7.1	mm,	6.9	mm,	6.8	mm,	7.1	mm,	6.9	
mm,	 6.5	mm	and	 6.5	mm,	 for	 the	 peripheral	 catheters	 1	 to	 7,	 respectively.	 The	 first	





































Catheter	 Diodes	 No.	of	Gaus.	terms	 R2	values	
	 DHR	 DLR	 DHR	 DLR	 DHR	 DLR	
1	 D2	 D3	 4	 3	 1	 0.9998	
2	 D2	 D3	 4	 3	 1	 1	
3	 D3	 D2	 4	 2	 1	 0.9998	
4	 D3	 D1	 4	 2	 1	 0.9998	
5	 D1	 D3	 4	 2	 0.9995	 0.9999	
6	 D1	 D2	 3	 2	 0.9999	 0.9998	
7	 D2	 D1	 4	 2	 1	 0.9998	

















DIODE	#	 Gaus	term	 C.1	 C.2	 C.3	 C.4	 C.5	 C.6	 C.7	 CENTRAL	
D1	
a1	 	 	 	 9.25	 12.31	 40.42	 7.88	 10.29	
b1	 	 	 	 36.97	 41.99	 36.23	 36.49	 36.81	
c1	 	 	 	 12.78	 3.76	 4.73	 11.22	 10.76	
a2	 	 	 	 8.46	 15.64	 42.47	 10.06	 -5.69	
b2	 	 	 	 36.96	 51.66	 36.09	 36.47	 59.02	
c2	 	 	 	 33.41	 15.12	 10.26	 29.36	 21.09	
a3	 	 	 	 	 64.17	 12.53	 	 13.78	
b3	 	 	 	 	 37.73	 36.70	 	 44.33	
c3	 	 	 	 	 6.85	 28.64	 	 30.96	
a4	 	 	 	 	 35.12	 	 	 	
b4	 	 	 	 	 42.13	 	 	 	
c4	 	 	 	 	 21.98	 	 	 	
D2	
a1	 50.19	 0.59	 2.94	 		 		 5.54	 0.20	 		
b1	 36.98	 36.28	 36.41	 	 	 35.58	 16.57	 	
c1	 4.39	 4.06	 13.81	 	 	 12.13	 4.20	 	
a2	 52.09	 6.38	 6.14	 	 	 7.38	 25.19	 	
b2	 36.79	 36.25	 36.63	 	 	 35.76	 36.91	 	
c2	 9.11	 10.15	 34.94	 	 	 31.51	 11.55	 	
a3	 0.68	 9.77	 	 	 	 	 15.80	 	
b3	 20.76	 35.91	 	 	 	 	 37.05	 	
c3	 3.40	 20.97	 	 	 	 	 5.96	 	
a4	 12.56	 1.97	 	 	 	 	 9.12	 	
b4	 36.88	 74.61	 	 	 	 	 37.37	 	
c4	 26.25	 441.30	 		 		 		 		 30.38	 		
D3	
a1	 0.63	 2.54	 55.32	 0.00	 5.97	 	 	 5.63	
b1	 33.97	 38.88	 39.26	 38.53	 39.14	 	 	 39.08	
c1	 3.34	 6.52	 4.10	 0.05	 12.95	 	 	 9.81	
a2	 5.39	 7.03	 18.58	 16.48	 7.54	 	 	 3.88	
b2	 34.17	 38.93	 39.20	 39.61	 39.45	 	 	 40.05	
c2	 34.37	 34.59	 15.17	 6.21	 32.57	 	 	 44.28	
a3	 2.82	 10.11	 47.66	 24.09	 	 	 	 9.25	
b3	 33.78	 38.51	 39.27	 39.55	 	 	 	 39.19	
c3	 11.88	 13.75	 7.94	 12.01	 	 	 	 18.45	
a4	 	 	 5.86	 9.10	 	 	 	 	
b4	 	 	 39.62	 40.05	 	 	 	 	
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In	 this	 study,	 an	 innovative	 prototype	 of	 a	 MVC	 applicator	 with	 embedded	 diode	
detectors	was	produced.	Preliminary	measurements	on	a	“simple”	and	on	ten	different	
clinical	 treatment	 plans	 have	 demonstrated	 the	MVC	 system’s	 ability	 to	monitor	 the	
HDR	source	throughout	the	entire	dose	delivery	phase,	providing	in	vivo	and	real	time	
QA	of	the	delivered	treatment	by	comparing	it	to	the	prescribed	plan.	The	system	is	in	





spontaneous	 afterloader	 malfunction,	 incorrect	 applicator	 and	 indexer	 lengths,	
mistakes	 in	 transfer	 tube	 connections,	 source	 calibration,	 and	 administration	 of	 the	
incorrect	 treatment	 plan.	 The	 proposed	 pre-calibrated	 MVC	 system	 is	 the	 first	
prototype	of	the	MVC	applicator	with	embedded	diode	detectors	that	is	able	to	provide	
dwell	 positions	 and	 times	 in	 real	 time	 with	 generally	 sub-mm	 and	 sub-second	
accuracy.		
	
The	 MVC	 system	 can	 be	 pre-calibrated	 via	 a	 relatively	 easy	 method,	 and	 source	
positions	and	times	can	be	obtained	in	real	time	without	any	assumptions	or	particular	
dose	 distribution	 calculations	 within	 the	 applicator/patient.	 Source	 positions	 are	
constrained	 along	 the	 central	 and	 peripheral	 catheters	 by	 the	 applicator,	 and	 the	
diodes	 have	 fixed	 positions	 with	 respect	 to	 the	 catheters.	 Thus,	 for	 each	 possible	
source	position	 in	one	of	 the	eight	 treatment	channels,	a	unique	solution	exists	 from	
the	combination	of	the	two	dosimeters	with	the	highest	responses.	This	solution	can	be	
determined	 experimentally	 prior	 to	 the	 use	 of	 the	 applicator	 and	 is	 valid	 without	
further	 recalibration	 in	 the	 case	 of	 stable	 diode	 response.	 Moreover,	 specific	





[154]	 or	 EPIDs	 [171],	 where	 more	 complex	 assumptions,	 pre-calibrations	 and	
calculations	have	to	be	performed	to	accurately	reconstruct	source	positions	inside	the	
patient	(for	example	complex	algorithms,	such	as	triangulation,	and	accounting	for	the	
response	 lag	 in	 the	 case	 of	 EPIDs).	 Source	 localization	 performed	 using	 plastic	
scintillation	 detectors	 benefits	 from	 their	 high	 sensitivity,	 angular	 and	 energy	
independence	 (as	 opposed	 to	 diodes),	 and	 small	 size	 that	 allows	 them	 to	 be	








For	 the	 proposed	 system,	 it	 is	 imperative	 that	 calibration	 takes	 place	 in	 the	 same	
conditions	 that	are	present	during	 treatment.	Moreover,	 the	diodes	are	 incorporated	
directly	over	the	dose	delivery	instrument,	eliminating	the	need	of	additional	steps	in	
the	 existing	 treatment	 procedure	 for	 the	 radiation	 oncologist.	 Prior	 to	 patient	
irradiation	 the	 diode	detectors	must	 simply	 be	 connected	 to	 the	 readout	 system.	To	
fully	 integrate	 the	 system	 into	 the	 QA	 workflow,	 the	 readout	 system	 should	 be	
connected	 with	 the	 afterloader	 treatment	 console	 for	 direct	 comparison	 between	
nominal	and	measured	(calculated	directly	on	the	console)	dwell	positions	and	times.	
	
Wang	 et	 al.	 (2014)	 [168]	 and	 Guiral	 et	 al.	 (2016)	 [167],	 who	 also	 equipped	 a	
commercial	MVC	applicator	with	four	[GaN-based]	dosimeters,	presented	results	that	
mainly	address	the	discrepancies	within	the	central	catheter.	Mean	dwell	position	and	











hospital	 staff.	 A	 source	 detection	 range	 of	 the	 proximal	 60-70	 mm	 of	 the	 vagina	 is	
sufficient	for	the	majority	of	clinical	applications	of	adjuvant	vaginal	cuff	BT	following	
hysterectomy,	where	the	proximal	3-5	cm	of	the	vagina	are	normally	treated	[172].	An	
increased	 number	 of	 diodes	 and	 their	 optimal	 positioning	 over	 the	 applicator	 could	
further	 extend	 the	 range.	 The	 temporal	 and	 spatial	 resolutions	 are	 also	 in	 principle	
sufficient,	 and	 would	 already	 allow	 the	 detection	 of	 significant	 delivery	 errors.	 A	
thorough	evaluation	of	the	system’s	ability	to	detect	specific	treatment	errors	will	be	
conducted	in	the	future.	
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An	intrinsic	limitation	of	the	developed	method	is	that	the	source	tracking	system	is	
incorporated	directly	on	the	MVC	applicator,	and	thus	is	not	able	to	detect	shifts	in	
applicator	position	and	rotation	throughout	the	treatment,	in	particular	with	respect	to	
the	planned	target	volume	and	the	surrounding	organs	at	risk.	The	use	of	the	system	
will	therefore	validate	that	the	delivered	treatment	is	in	accordance	with	the	planned	
one,	but	no	conclusions	can	be	drawn	about	the	delivered	dose	distribution.	In	vivo	
dose	measurements	in	the	urethra	or	rectum	[97,	114,	117,	173-176]	will	be	necessary	
to	provide	a	comprehensive	verification	of	the	delivered	treatment.	Further	in	vivo	
measurements	are	required	to	validate	a	potential	combination	of	dosimetry	and	
source	tracking	methods.	
	
	
9.6 Conclusions	and	recommendations	
	
The	applicator	prototype	with	embedded	diodes	for	HDR	source	tracking	has	shown	
great	potential	for	both	treatment	delivery	and	real-time	BT	treatment	verification	by	
demonstrating	a	sub-second	temporal	resolution	for	dwell	time	verification	and	a	sub-
millimetric	positional	accuracy	in	96.2	and	77.9%	of	reconstructed	dwell	positions	in	
the	central	and	peripheral	channels,	respectively.		
	
The	proposed	system	is	able	to	detect	treatment	errors	relating	to	source	position	and	
dwell	time	inside	the	applicator,	such	as	the	administration	of	the	wrong	treatment	
plan,	spontaneous	afterloader	malfunction	(altering	the	source	step	size	or	dwell	time),	
mistake	in	the	indicated	indexer	length,	and	systematic	errors	such	as	those	occurring	
as	a	result	of	incorrect	source	calibration.		
	
The	MVC	HDR	BT	verification	system	can	be	improved	in	future	studies	by	placing	
additional	diodes	on	the	applicator	surface	as	well	as	positioning	detectors	at	a	higher	
distance	from	one	another	on	the	longitudinal	plane	to	decrease	uncertainties	in	close	
proximity	to	the	diode’s	sensitive	volume.	Future	studies	to	evaluate	the	MVC	system’s	
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ability	to	detect	specific	treatment	errors	and	to	investigate	the	possible	combination	
of	the	MVC	system	with	in	vivo	dosimetry	methods	will	be	conducted	in	the	future.	
	
	
	
	
	
	
	
	
	
Chapter	10	
	
Retrospective	and	real-time	dosimetry:	
recommendations	and	conclusions	
	
	
10.1 Retrospective	dosimetry	
	
Solid-state	semiconductor	dosimetry	has	been	successfully	applied	to	the	
visualization	and	spatially	resolved	dose	rate	measurement	of	intact	sediment	
samples,	both	artificially	produced	and	natural	samples,	from	key	archeological	and	
hominin	sites.	The	proposed	Timepix	methodology	allows	the	measurement	of	
samples	resinated	as	per	micromorphology	procedure,	preserving	the	
microstratigraphic	context	of	the	sample	during	burial.	A	superior	spatial	resolution	
of	sample	environmental	dose	rates	that	is	well	within	the	3-mm	beta	particle	range	
has	been	achieved.	
	
High	dose	rate	inhomogeneity	has	been	shown	within	the	sample	from	the	Liang	
Bua	Cave,	while	dose	rates	within	the	Denisova	Cave	sample	have	demonstrated	
higher	spatial	uniformity	and	a	normal	dose	rate	distribution.	Based	on	the	results,	
radioemitter	inhomogeneity	may	affect	sample	age	by	up	to	70%.	
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Future	studies	employing	the	Timepix	for	sediment	measurement	have	the	potential	
to	achieve	a	3D	visualization	of	dose	rates	within	samples	by	measuring	thinner	
slices.	Dose	rate	calibration	can	be	improved	to	further	minimize	dose	rate	
conversion	errors.	Energy	calibration	of	the	Timepix	can	be	applied	to	evaluate	the	
energy	deposition	of	detected	particles,	and	explore	the	use	of	this	feature	for	
isotope	identification.	Furthermore,	Timepix	measurement	results	can	be	modeled	
using	the	Geant4	simulation	platform	to	assess	the	effect	on	the	dose	absorbed	by	
the	detector	grains,	and	obtain	a	distribution	of	singe-grain	ages.	
	
This	study	is	an	important	step	towards	improving	the	accuracy	and	precision	of	
chronology	in	both	geological	and	archeological	contexts,	which	can	ultimately	
deepen	our	knowledge	on	the	evolution	and	dispersion	of	humankind.	
	
	
10.2	 Real-time	dosimetry	
	
The	combination	of	in	vivo	dosimetry	and	HDR	source	tracking	systems	investigated	
in	this	thesis	have	the	potential	to	detect	errors	that	would	remain	unknown	
without	real-time	or	post-treatment	verification.	The	precision	of	the	source	
tracking	system,	which	is	able	to	provide	excellent	QA	of	the	BT	source	throughout	
the	entire	procedure,	in	combination	with	point-measurements	of	absorbed	dose	in	
OARs,	can	be	used	in	real	time	to	prevent	or	provide	awareness	of	a	multitude	of	
potential	missteps	in	gynecological	HDR	BT	treatments.	Epi	diodes	in	the	proposed	
HDR	source	verification	system	are	able	to	detect	errors	such	as	source	calibration,	
spontaneous	afterloader	malfunctions,	incorrect	applicator	or	indexer	lengths,	and	
misconnections	of	transfer	tubes.	MOSkin	dosimeters	assembled	over	the	DRP	can	
be	used	to	alert	of	any	dose	discrepancies	as	a	result	of	organ	and/or	applicator	
motion.	Both	of	the	systems	can	verify	that	the	correct	plan	is	being	delivered	to	the	
patient,	and	can	be	easily	incorporated	into	the	existing	clinical	treatment	flow.			
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IVD	can	identify	errors	resulting	from	anatomical	differences,	such	as	inter-	or	intra-
fraction	organ	swelling	or	motion,	however	only	if	these	directly	affect	the	dose	
delivered	at	the	points	of	measurement.	In	the	cases	that	the	doses	in	those	regions	
are	affected,	the	introduction	of	post-treatment	imaging	would	provide	a	more	
comprehensive	quality	assurance	of	the	delivered	treatment,	allowing	post-
treatment	reconstruction	of	the	delivered	dose	distribution.	The	three	components	
of	comprehensive	HDR	BT	treatment	QA	are	shown	in	figure	10.1.	
	
	
Figure	10.1	Three	components	of	comprehensive	HDR	BT	QA.	
	
Future	applications	of	the	DRP	procedure	for	IVD	are	recommended	to	employ	the	
recently	developed	wireless	MOSkin	reader	system,	allowing	readout	without	the	
necessity	of	the	long	cables.	Moreover,	delivered	and	planned	rectal	wall	dose	
discrepancies	should	be	evaluated	in	real-time,	as	opposed	to	the	post-treatment	
evaluation	performed	in	this	study.	A	newly	assembled	MVC	system	that	employs	a	
higher	number	of	diodes	with	optimized	diode	positioning	is	recommended	to	test	
system	ability	to	detect	specific	treatment	errors.	Studies	of	real-time	dose	and	HDR	
source	monitoring	should	be	implemented	and	evaluated	in	future	studies	to	
determine	its	efficacy	in	alerting	of	dose	discrepancies	above	the	accepted	error	
margin.		
	
It	is	important	that	the	frequency	and	types	of	treatment	errors	are	shared	and	
discussed	among	radiotherapy	staff,	so	that	these	results	can	lead	to	an	evolution	of	
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quality	management	systems	in	the	clinic,	and	contribute	to	the	reduction	of	
uncertainties	and	potential	systematic	errors.	This	in	turn	will	improve	cancer	care	
for	the	patient,	and	provide	another	stepping-stone	in	our	battle	with	cancer.	
	
	
10.3	 Final	conclusions	
	
In	this	thesis,	solid-state	semiconductor	dosimetry	has	united	the	fields	of	
geoscience	and	medical	physics.	Radiation	measurement	techniques	have	been	
developed	both	for	sediment	dating,	by	applying	the	Timepix	pixelated	detector,	and	
for	radiotherapy	treatment	verification,	by	applying	MOSkin	and	diode	detectors.	
Using	these	methods,	spatially	resolved	sediment	dose	rates	have	the	potential	to	
improve	the	accuracy	and	precision	of	dating	and	allow	a	better	understanding	of	H.	
sapiens’	past,	while	real	time	radiotherapy	treatment	verification	has	the	potential	
to	improve	the	quality	and	longevity	of	life	for	present-day	and	future	H.	sapiens.	
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